Open Nav

Abreos Biosciences, Inc.

  • Bradley Messmer, Abreos Biosciences

Investment for $5M Series A

  • Date:Thursday, October 18
  • Time:3:15 PM - 3:30 PM
  • Room:Elizabethan C
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:Precision medicine company developing therapeutics complemented by personalized dosing. Abreos Biosciences is planning to develop a novel therapeutic for treatment of multiple sclerosis, a chronic neurological disease. Our approach will be to study a well characterized biologic in a new indication facilitated by our platform for precision personalized dosing.
  • Company
  • Company HQ City:La Jolla
  • Company HQ Country:United States
  • Company HQ State:California                  
  • Main Therapeutic Focus:CNS/Neurological
  • Lead Product in Development :ABR101
  • Development Phase of Primary Product:Pre-Clinical
  • Additional Information/Comments:Inverting therapeutic value for biologics through personalized dosing
  • Total Amount Raised to Date, In All Rounds:$8.5M
Bradley Messmer
Abreos Biosciences